SynthesisClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014
Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis.
Synthesis in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed.
- Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults.The Journal of clinical investigation · 2024Trial
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.The lancet. HIV · 2021Trial
- Measles Immunity at 4.5 Years of Age Following Vaccination at 9 and 15-18 Months of Age Among Human Immunodeficiency Virus (HIV)-infected, HIV-exposed-uninfected, and HIV-unexposed Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Effect of HIV exposure and timing of antiretroviral therapy initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and hepatitis B vaccines.Expert review of vaccines · 2019Trial
- Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.The Lancet. Infectious diseases · 2016Trial
- Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.Journal of the International AIDS Society · 2016Trial
- Antiviral Innate Immune Activation in HIV-Infected Adults Negatively Affects H1/IC31-Induced Vaccine-Specific Memory CD4+ T Cells.Clinical and vaccine immunology : CVI · 2015Trial
- Heterogeneity of baseline immune activation and SARS-CoV-2 vaccine responses in people with HIV: a multicenter prospective study.AIDS (London, England) · 2026Article
- Reduced HAV IgG Seropositivity Among Unvaccinated People Living with HIV: The Weak Shield.Tropical medicine and infectious disease · 2026Article
- Humoral Immunogenicity of SARS-CoV-2 mRNA Primary Vaccination Among People with HIV.Microorganisms · 2026Article
- Modeling of longitudinal immune profiles reveals distinct immunogenic signatures following five COVID-19 vaccinations among people living with HIV.Patterns (New York, N.Y.) · 2026Article
- Altered Cytokine-Induced STAT3 and STAT5 Activation of Peripheral T Follicular Helper Cells Contributes to Vaccine-Non-Responsiveness in Aging and HIV.Aging cell · 2026Article
- Hepatitis B virus vaccination in people with HIV: what's new?Current opinion in HIV and AIDS · 2026Review
- Incidence of Chronic Hepatitis B Virus Infection Among People With HIV in Yunnan Province, China: A Retrospective Observational Cohort Study (2004-2024).Open forum infectious diseases · 2026Article
- A real-world pattern on the long-term durability of the immune response to hepatitis B vaccination among people living with HIV in China: an 8.5-year retrospective study.Frontiers in public health · 2026Article
- Challenges in the Vaccination of HIV-Infected Individuals.Vaccines · 2025Review
- Booster dose reshapes SARS-CoV-2 RBD-specific B cell immunity in people living with HIV.Journal of translational medicine · 2025Article
- Ageing with HIV-1: immunological challenges for effective vaccination.Immunity & ageing : I & A · 2025Review
- Neutralizing and binding antibodies are a correlate of risk of COVID-19 in the CoVPN 3008 study in people with HIV.Nature communications · 2025Article
- Diminished Long-term Vaccine Antibody Persistence in Perinatally Youth Living With HIV on cART.Open forum infectious diseases · 2025Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccine-induced antibodies may wane more quickly in persons living with human immunodeficiency virus (HIV) than in healthy individuals. We reviewed the literature on vaccines routinely recommended in HIV-infected patients to estimate how seroprotection decreases over time in those who initially responded to immunization. For each study retrieved from the literature, the decrease of seroprotection was modeled with a log binomial generalized linear model, and data were pooled in a meta-analysis to provide estimates of seroprotection 2 and 5 years after the last vaccine administration. Our analyses confirmed that the duration of seroprotection was shorter in HIV-infected patients and that with current guidelines, a substantial proportion of patients would have lost protective antibodies before a booster was proposed. We therefore discuss the implications for the monitoring of antibody levels and timing of revaccination in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.